Managed Healthcare Executive

Atopic dermatitis care advances in 2025 with new biologics, topicals and oral therapies

Atopic dermatitis’ (AD) deeper complexities were exposed in 2025. Once seen mainly as a visible skin condition, AD is now widely recognized as a long-lasting inflammatory disease that affects sleep, ...
Medscape

Multiple AD Treatment Options Leading to Individualized Therapy

Once limited to nonspecific anti-inflammatory therapies, expanding treatment options for atopic dermatitis are allowing therapy to be individualized.
Agence France-Presse

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib ...

Takeda's AI-crafted psoriasis pill succeeds in late-stage studies

Dec 18 () - Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using ...

SOLIGENIX, INC.: Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

Study results support advancing SGX945 in this difficult-to-treat orphan disease Results suggest potential durability of response for maintenance therapy PRINCETON, N.J., Dec. 18, 2025 ...
The Malaysian Reserve

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet’s Disease Published in Rheumatology (Oxford)

Study results support advancing SGX945 in this difficult-to-treat orphan diseaseResults suggest potential durability of ...